PIPELINE

Osivax universal influenza vaccine candidate

Current seasonal vaccines triggering an antibody response against surface antigens (hemagglutinin and neuraminidase) are only partially effective, especially for patients over 65 years old : 25% effectiveness in the 2016-17 season in the US (3)

A paradigm shift is essential in influenza vaccination

Osivax is developing a game-changing universal influenza vaccine

Osivax’s vaccine targets the NucleoProtein (NP), a highly conserved internal antigen, much less prone to mutations than the traditional surface antigens targeted by current flu vaccines, thus alleviating the need for annual updates​

oligoDOM® technology enables the transformation of the NucleoProtein into a highly immunogenic antigen to trigger powerful B- and T-cells immune responses